cyrilzakka/clinical-trials huggingface dataset:
Parental Acceptance and Perception of Silver Diamine FlouridApplication Among A Sample of Egyptian Children.

Dental caries can be prevented or arrested . Moreover, preventive measures for dental caries are more cost effective than emergency room visits or restorative treatments when the illness has been established . One of the recent preventive methods of dental caries is silver diamine flouride . SDF has been used as an alternative treatment for caries prevention and arrest . Several studies showed that silver diamine flouride cause staining of the treated teeth . However, parents have different attitudes toward using SDF considering its positives and negatives.

Dental caries is one of the most common diseases in the world, with a prevalence of 69%-79% . Early childhood caries (ECC) has been recognized by the American Dental Association as an important public health issue and was defined as presence of 1 or more decayed, missing, or filled tooth surfaces (dmfs) in any primary tooth in a preschool-aged child . Caries was known to be managed through two main approaches: Treatment, which includes drill and fill which is a challenge specially in minimally cooperative children and the second approach is prevention which depends on cease the process of caries formation at an early stage which is more effective . One of the recently marketed preventive measures of dental caries is silver diamine fluoride (SDF) .

In 2014, SDF was approved by the US Food and Drug Administration as a treatment for dentinal sensitivity .It was proven to be a cost-effective, minimally invasive, and handy treatment . Silver diamine flouride is easy to apply in a minimally cooperative individual . More important, it has shown a noticeable success rate in caries prevention, especially in early childhood caries cases . It provides families with an alternative solutions for managing dental caries, particularly if caries was detected at an early stage . Moreover, it could save time and effort for both families and dental teams.

The major downside of SDF is the unesthetic permanent black discoloration of the arrested lesion , which could affect parental acceptance for the treatment and may result in shifting to another esthetically acceptable treatment.

Eligibility Criteria:
Inclusion Criteria:

* parents whose children with early childhood caries. Accepting participations.

Exclusion Criteria:

* Refusal of participation.
Tele-Nursing Follow-Up After Open Heart Surgery

Introduction: Failure to follow-up patients by healthcare professionals after discharge may increase the development of anxiety and complications in patients.

Aim: The aim of this study is to determine the effects of tele-nursing method to patients who have undergone Open Heart Surgery (OHS) after discharge on anxiety and some other complications.

Material and Methods:This quasi-experimental randomized controlled study, which was conducted in a private hospital between November 2020 and April 2021, included 75 patients, 38 from the Intervention (IG) and 37 from the Control Group (KG). IG and CG patients were provided routine treatment and care. In addition to the IG, training and counselling were provided at least four times by phone calls between the first week after discharge and the end of the first month. Descriptive Form and State-Trait Anxiety Inventory (STAI-S and T) were administered to all patients before discharge, and STAI-S was administered at the end of the first month after discharge. Post-discharge complications were evaluated by medical doctor in both groups. These data, number of hospitalization and readmission rates were obtained from hospital records.


Eligibility Criteria:
Inclusion Criteria:

* Eighteen years and older,
* Able to speak and understand Turkish,
* Without hearing, comprehension, vision and speech problems,
* Open heart surgery for the first time,
* Those who were not diagnosed with depression or anxiety disorder before surgery and didn't use medication for this purpose,
* Having a mobile phone that can take photos by herself/himself or her/his attendants,
* No serious complications to delay hospital discharge,
* Patients who volunteered to participate were included in the study.

Exclusion Criteria:

Patients who wished to withdraw from the study after volunteering were excluded from the study.
Cyanoacrylate Closure for Treatment of Venous Leg Ulcers

Venous leg ulcers (VLUs) are a common wound with significant morbidity and cost, and suboptimal therapeutic options. VLUs result from chronic venous insufficiency, including venous reflux and post-thrombotic syndrome. VLU can take from months to years to heal, and 54-78% recur. Current therapies include wound, compression therapy, and medications. These treatments can increase the rate of healing, and reduce recurrence, however these therapies can be burdensome, painful, and ineffective, and despite these therapies, \~50% of wounds become chronic. Chronic VLUs can be painful, malodorous, and infected, and they often significantly limit an individual's function and mobility. An emerging therapy for symptomatic venous reflux is the closure of the culprit vein by endovenous closure with a cyanoacrylate adhesive implant. Recent studies show cyanoacrylate closure (CAC) to be a safe and effective treatment for varicosities resulting from symptomatic incompetent great saphenous veins. This study will evaluate the safety and effectiveness of CAC for VLUs.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years old at time of screening;
2. Venous leg ulcer;
3. Venous insufficiency (\>0.5 seconds; confirmed by Doppler within last 6 months);
4. ABI of ≥0.9;
5. Capable of understanding the study and providing informed consent.

Exclusion Criteria:

1. Previous hypersensitivity reactions to the VenaSealTM adhesive or cyanoacrylates;
2. Acute superficial thrombophlebitis;
3. Bilateral treatment
4. Thrombophlebitis migrans;
5. Deep venous thrombosis;
6. Deep venous incompetence or occlusion in external iliac or distal veins in the affected extremity (as assessed based on spontaneity, phasicity, augmentation, pulsatility, and compressibility on ultrasound);
7. Post-thrombotic syndrome;
8. Acute sepsis;
9. Coagulation disorders;
10. Radiation or chemotherapy within 3 months of study;
11. Pregnant or lactating females;
12. Uncontrolled diabetes (HbA1c \>10%);
13. Diabetic foot ulcers;
14. Current use of systemic anticoagulation;
15. Previous treatment of target vein;
16. Tortuous veins;
17. Current participation in another interventional study, or participation within 30 days prior to screening;
18. Inability to tolerate compression, or to receive endovenous treatment.
Comparison of NT Vs Body Weight Supported TT Along With CT on Lower Extremity in Chronic Stroke Patients

To determine the effect of Neurodevelopment Treatment vs Body Weight Supported Treadmill Training along with conventional therapy on lower extremity among chronic stroke patients.


Eligibility Criteria:
Inclusion Criteria:

* Application of M-Cog test for checking patients cognition.
* Chronic ischemic stroke patients.
* Both Male and Female Patients.
* Patients of 35 or above years of age.

Exclusion Criteria:

* Patients with history of recurrent stroke.
* Patients with lower limb fractures or dislocations.
* Patients with Peripheral vascular disease
* Patients with skin discoloration or skin ulcers.
Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study

The aim of the present study is to develop a measurement protocol for optimal imaging of the anterior segment of the eye, including anterior chamber angle, Schlemm's canal, filtering bleb and pseudoexfoliation deposits on the lens based on measurements in patients with glaucoma and PEX. In glaucoma the structures of the anterior chamber are important for classification, therapy, progression and prognosis and imaging of the angle between the iris and the cornea is the key for open angle and closed angle glaucoma differential diagnosis. For this purpose, a customized ultrahigh resolution Spectral Domain OCT will be used to validate whether the protocol can also be more widely applied in these patients. Based on the obtained measurement protocol, further studies investigating anatomy and pathophysiology of the anterior segment of the eye as well as surgical outcome in patients with glaucoma and PEX can be planned.

The aim of the study is to develop a measurement protocol for OCT imaging and characterization of the anterior chamber in glaucoma patients.


Eligibility Criteria:
Inclusion Criteria:

* Men and women aged over 18 years

For patients with primary open angle glaucoma:

* Diagnosed primary open angle glaucoma
* Visual field defects and optic nerve head appearance characteristic for glaucoma
* Open anterior chamber angle as evidenced by gonioscopy
* No previous glaucoma surgery
* No previous cataract surgery

For patients with primary angle closure:

* Angle closure predisposition as evidenced from goniosocopy
* No previous glaucoma surgery

For patients with neovascular glaucoma:

- Neovascularization in the anterior chamber angle

For patients with pseudoexfolation deposits on the lens:

* PEX glaucoma as evidenced from slit lamp examination
* Visual field defects and optic nerve head appearance characteristic for glaucoma
* Open anterior chamber angle as evidenced by gonioscopy
* No previous glaucoma or cataract surgery

For glaucoma patients with filtering bleb after trabeculectomy:

* Patients with history of trabeculectomy secondary to open angle glaucoma in the previous three months
* No cataract surgery

For healthy volunteers:

* No evidence of ocular disease
* No degenerative changes in the retina in funduscopy after mydriasis
* Ametropia less than 3 dpt.

Exclusion Criteria:

* Presence of any abnormalities preventing reliable measurements as judged by the investigator
* Pregnancy, planned pregnancy or lactating
* Ocular inflammation and ocular disease interfering with the study aims as judged by the investigator
Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection.

The purpose of this study is to compare the survival rate according to the presence or absence of 14v lymph node dissection. Actually, if the 14v lymph node metastasis is suspected before surgery, it is excluded from the study. In a retrospective study conducted in our hospital, we compared the patients with the 14v lymphadenectomy group and those without the 14v lymphadenectomy group, the survival rate of the 14v lymphadenectomy group was 11% higher than that of the 14v non-lymphadenectomy group.Previous studies have suggested that the presence of metastatic lymph nodes in the 14v lymph node is not good and that removal of the 14v lymph node does not affect prognosis. However, if the lymph node is a continuous tissue and the transition to the 14v lymph node is confirmed microscopically, a negative prognosis may be expected because it is likely that the cancer has spread to the distal lymph node. In addition, inadequate resection of the lymphatic or 14v lymph node adjacent to the 14v lymph node in the absence of evidence of metastasis of the 14v lymph node under microscopic examination indicates that cancer may spread even after curative surgery, To prevent cancer metastasis.

Eligibility Criteria:
\<Inclusion Criteria\>

* Histologically proven primary gastric adenocarcinoma
* T3N+, T4N+ by CT scan (AJCC 7th classification)
* Distal margin of gastric cancer Location of distal margin of gastric cancer ; antrum, or angle of the stomach
* No evidence of other distant metastasis
* Age ≥ 20 year old
* Performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
* No prior treatment of chemotherapy or radiation therapy against any other malignancies, and no prior treatment for gastric cancer including endoscopic mucosal resection
* Adequate organ functions defined as indicated below:

  1. WBC 3000/mm3 - 12,000/mm3
  2. \> Serum Hemoglobin 8.0 g/dl
  3. \> Serum Platelet 100 000/mm3
  4. \< Serum AST 100 IU/l
  5. \<Serum ALT 100 IU/l
  6. \< Total Bilirubin 2.0 mg/dl
* Written signed informed consent

\<Exclusion Criteria\>

* Active double cancer (synchronous double cancer and metachronous double cancer within five disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer)
* Gastric remnant cancer
* Pregnant or breast-feeding women
* Mental disorder(diagnosed with mental disorder on medical record)
* Systemic administration of corticosteroids(include Herbal Medication)
* Unstable angina or myocardial infarction within 6 months of the trial
* Unstable hypertension
* Severe respiratory disease requiring continuous oxygen therapy
* Indications Total gastrectomy
* Borrmann type IV in the preoperative examination (including localized)
* Suspected LN # 14v metastasis during surgery
* Indications Pancreatectomy
* Suspected a metastasis of CT scans LN # 13, LN # 14
* Clinical stage IV group is suspected or confirmed during surgery
Endoscopic Submucosal Injection of Indocyanine Green Before Laparoscopic Gastrectomy

Prospective registry study of endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy

To observe the imaging result of endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy, and analyze the relevant factors, so as to guide the operation of preoperative indocyanine green submucosal injection better.

This study is prospective and observational. In order to analyze the related factors that affect the imaging effect, we enrolled patients who were to undergo indocyanine green fluorescence imaging for laparoscopic radical gastrectomy.

Eligibility Criteria:
Inclusion Criteria:

* patients who were to undergo indocyanine green fluorescence imaging for laparoscopic radical gastrectomy.

Exclusion Criteria:

* have simultaneously other cancer

  * have severe systemic inflammatory disease ,serious illness such as diabetes, chronic lung diseases
  * have upper gastrointestinal surgery
  * Indocyanine green or iodine allergy
  * the period is too late or the tumor is too large to carry on a laparoscopy assisted radical distal gastrectomy
Construction and Evaluation of China's Advanced Pancreatic Tumor Big Data Center

This study is a multi-center observational study. The start time for data collection is August 31, 2019. Patients who have been treated at our institution from August 31, 2019, who were diagnosed with pancreatic tumors on or before August 31, 2019 (diagnosed in our hospital or outside hospitals) would all meet the inclusion conditions of the study and be considered enrollment. Patients' baseline and treatment data will be collected under informed concent. The combination of medical big data governance and the leading technology of the big data platform uses real world data to improve the quality and efficiency of pancreatic tumor diagnosis, treatment and scientific research.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 18, both male and female;
2. Patients with primary pancreatic tumor diagnosed by histology, cytology or imaging;
3. Clinical or pathological staging is locally advanced or metastatic pancreatic tumor (newly diagnosed or after surgery and other treatments);
4. You can accept or have not received surgery, chemotherapy, radiotherapy, local treatment or traditional Chinese medicine for tumors;
5. The subject voluntarily joined the study and signed an informed consent form voluntarily.

Exclusion Criteria:

1. Pancreatic tumors are evaluated as metastatic lesions, not primary tumors of the pancreas.
Ultrasonic Neuromodulation for Treatment of Cognitive Impairment

This study will evaluate a new form of non-invasive deep brain therapy for individuals with Alzheimer's disease. Low-intensity transcranial focused ultrasound stimulation will first be delivered using a range of stimulation parameters during psychophysical and physiological monitoring. A well-tolerated stimulation protocol will be selected for subsequent testing in a blinded randomized sham-controlled cross-over trial. The trial will evaluate brain target engagement using magnetic resonance imaging, PET imaging, and numerical scales of cognitive performance.


Eligibility Criteria:
Inclusion Criteria:

* Mild cognitive impairment or mild dementia due to Alzheimer's disase (AD) with confirmed AD biomarkers (Amyloid PET or CSF)
* Age 65-80
* MOCA \> 18

Exclusion Criteria:

* Evidence of cerebral amyloid angiopathy or stroke within 1 year
* Clinical symptoms or findings suggestive of alternative diagnosis or co-pathology
* Inability to complete MRI
* Suicidal ideation
An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice

This observational, multi-center study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in renal anemia correction in dialysed patients in daily clinical practice. Patient will receive Mircera according to local summary of product characteristics. Data will be collected for 12 months.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>/=18 years of age
* Adequate iron status
* Signed informed consent form

Exclusion Criteria:

* Anemia due to non-renal causes
* Where investigator considers the patient unsuitable for inclusing for other reasons (e.g. severe co-morbidities as active bleeding, infections or cancer)
* Pregnant or lactating female patients
* Any contraindications against treatment with Mircera (according to local Summary of Product Characteristics)
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.

All patients meeting inclusion/exclusion criteria from inpatient database from 1/1/02-9/30/10.

Eligibility Criteria:
Inclusion Criteria:

* MRSA and pneumonia cases by ICD-9 code identification.
* Diagnosis included during inpatient stay.
* Treatment initiation in hospital.

Exclusion Criteria:

* Death of discharge within 3 days of treatment initiation.
* Exposure to other treatments with MRSA activity.
Unleashing Unpredictability: The Batman Project and Its Impact on Prosocial Behavior and Awareness

The proposed study is an observational investigation that aims to examine the impact of an unexpected and unusual event on prosociality within the Milan metro. The event is the simple presence, in the underground car, of a student wearing a Batman suit. The main objective is to assess whether or not the presence of the unusual event influences prosocial behaviour towards a student pretending to be pregnant. During the study, the student, equipped with a sponge prosthesis to simulate a pregnancy will board the underground. She will be asked not to interact with anyone, but to simply look at her phone. In the experimental condition, an individual dressed as Batman will enter the carriage (through a different door than the one used by the student). In the control condition, on the other hand, no one will show up in costume. In addition, the observer will try to gather information on the reason for this prosocial behaviour, noting down the answer given.


Eligibility Criteria:
Inclusion Criteria:

* Being a passenger in the metro

Exclusion Criteria:

* Metro too crowded
* Seats available
The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation.

The purpose of this study is to evaluate the diagnostic value of serum NT - proBNP in stroke associated with nonvalvular atrial fibrilltion.

All included in the cases in 7 days of blood samples, the detection of serum NT - proBNP.Through the single factor analysis to determine the serum NT - proBNP central source sex stroke prediction values.

Eligibility Criteria:
Inclusion Criteria:

* 18 ≤ Age ≤ 85;
* Meet the clinical diagnostic criteria for acute ischemic stroke;
* onset within 7 days;

Exclusion Criteria:

* Severe systemic disease (chronic inflammation, infection, blood system diseases, cancer, kidney failure, liver failure,heart failure);
* Nearly a month history of myocardial infarction;
* pregnant;
* Serious neurological disease that the diagnosis is unclear;
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

The purpose of this study is to analyze drug-drug interactions of CBD on co-administered Morphine as first step in understanding CBD-opioid interactions.

This is an inpatient, single-blind, non-randomized, 1-sequence study involving healthy subjects who have used opioids for recreational use. The primary objective of the study is to establish the pharmacokinetic parameters of morphine 30 mg when administered with and without CBD 350 mg b.i.d. and CBD 700 mg b.i.d.

Eligibility Criteria:
Inclusion Criteria:

* Must understand and provide written informed consent prior to the initiation of any protocol-specific procedures.
* Males and females 18 to 55 years of age, inclusive.
* Body mass index (BMI) ranging from 18 to 34 kg/m2, inclusive, and body weight of 56 kg and above.
* Adequate venous access as assessed by an investigator at screening.
* No clinically significant concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead ECG.
* Recreational opioid use (i.e., defined as prescription opioid use for nontherapeutic purposes on at least 3 occasions within the previous year and at least once in the 12 weeks prior to screening), experienced in using opioids of approximately 30 mg morphine equivalents and not seeking treatment for Opioid Use Disorder.
* If of childbearing potential, a female study subject must agree to use 1 of the accepted contraceptive regimens from at least 30 days prior to the first administration of the study medication, during the study and for at least 30 days after the last dose of the study medication

  1. An acceptable method of contraception includes abstinence from heterosexual intercourse or intrauterine device (with or without hormones)
  2. OR agrees to use a double barrier method (e.g., condom and spermicide) during the study and for at least 30 days after the last dose of the study medication. Oral contraceptives are prohibited.
  3. If a female of non-childbearing potential, she should be surgically sterile (i.e., has undergone compete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses), as confirmed by FSH level.
* A male study subject must agree to use a double barrier method (e.g., condom and spermicide) and agree to not donate sperm during the study and for at least 90 days after the last dose of the study medication.
* Agree not to ingest alcohol, drinks containing caffeine \>500 mg/day (e.g., Coca Cola®, tea, coffee, etc.), or grapefruit/grapefruit juice or participate in strenuous exercise 72 hours prior to admission through the last blood draw of the study.
* Able to speak, read, and understand English sufficiently to allow completion of all study assessments.
* Must be willing and able to abide by all study requirements and restrictions.

Exclusion Criteria:

* Contact site directly for more information